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Objectives: Stroke risk immediately after TIA defined by time-based criteria is high, and prognos-
tic scores (ABCD2 and ABCD3-I) have been developed to assist management. The American
Stroke Association has proposed changing the criteria for the distinction between TIA and stroke
from time-based to tissue-based. Research using these definitions is lacking. In a multicenter
observational cohort study, we have investigated prognosis and performance of the ABCD2
score in TIA, subcategorized as tissue-positive or tissue-negative on diffusion-weighted imaging
(DWI) or CT imaging according to the newly proposed criteria.
Methods: Twelve centers provided data on ABCD2 scores, DWI or CT brain imaging, and
follow-up in cohorts of patients with TIA diagnosed by time-based criteria. Stroke rates at 7 and
90 days were studied in relation to tissue-positive or tissue-negative subcategorization, accord-
ing to the presence or absence of brain infarction. The predictive power of the ABCD2 score was
determined using area under receiver operator characteristic curve (AUC) analyses.
Results: A total of 4,574 patients were included. Among DWI patients (n  3,206), recurrent
stroke rates at 7 days were 7.1% (95% confidence interval 5.5–9.1) after tissue-positive and
0.4% (0.2–0.7) after tissue-negative events (p diff  0.0001). Corresponding rates in CT-imaged
patients were 12.8% (9.3–17.4) and 3.0% (2.0–4.2), respectively (p diff  0.0001). The ABCD2
score had predictive value in tissue-positive and tissue-negative events (AUC  0.68 [95% con-
fidence interval 0.63–0.73] and 0.73 [0.67–0.80], respectively; p sig  0.0001 for both results,
p diff  0.17). Tissue-positive events with low ABCD2 scores and tissue-negative events with
high ABCD2 scores had similar stroke risks, especially after a 90-day follow-up.
Conclusions: Our findings support the concept of a tissue-based definition of TIA and stroke, at
least on prognostic grounds. Neurology® 2011;77:1222–1228
GLOSSARY
ACS  acute coronary syndrome; ASA  American Stroke Association; AUC  area under the receiver operator characteristic
curve; CI  confidence interval; DWI  diffusion-weighted MRI; ED  emergency department.
The risk of recurrent stroke immediately after TIA is high.1,2 The ABCD2 score is a prognostic
score for risk stratification in the acute phase,3 and its use has been recommended in national
guidelines.4–6 Recently, the ABCD2 score had been modified to incorporate brain and vascular
imaging to further improve prognostication (ABCD3-I).7,8
These prognostic studies were conducted in patients with TIA defined by time-based crite-
ria, recommended by the World Health Organization. 9,10 The American Stroke Association
(ASA) has recently proposed revising the definitions from time-based to tissue-based criteria,11
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advocating that stroke and TIA be distin-
guished by the presence or absence of brain
infarction identified on diffusion-weighted
MRI (DWI).12
Infarction on DWI has been found to be
associated with a high early stroke risk in a
number of studies,13–15 but methodology has
been inconsistent and sample sizes small. Al-
though CT is an inferior imaging modality in
TIA, its use continues where DWI is not
available or contraindicated. The association
between brain infarction on CT and early
stroke risk after TIA is less well studied. The
performance of prognostic tools has not been
studied in TIA and stroke defined by tissue-
based criteria.
We have therefore conducted a large, mul-
ticenter study of the early risk of recurrent
stroke after TIA, subcategorized as tissue-
positive or tissue-negative on either DWI or
CT according to the newly proposed crite-
ria.11 We have tested the hypothesis that the
ABCD2 score is prognostic when applied to
these groups.
METHODS This is an international, multicenter collaborative
study, the methods of which have been described previously.7 In
brief, 12 independent research centers were identified from a sys-
tematic review and electronic literature search as collecting suffi-
ciently detailed prospective data on ABCD2 score, brain imaging
results, and prognosis in cohorts of patients with TIA.16
Centers submitted previously unpublished tabular data on
cohorts of patients with TIA (defined by time-based criteria),
categorized by ABCD2 score and the presence or absence of
brain infarction, describing the outcome of recurrent stroke at 7
and 90 days. Patients were eligible if they gave written, informed
consent to participation in the study, had brain imaging in the
acute phase by either MRI or CT and follow-up to at least 7 days.
Patients with minor stroke according to time-based criteria or alter-
native, non-neurovascular diagnoses were excluded. Recurrent
stroke was defined as a new neurologic deficit of vascular origin
which lasted more than 24 hours or led to death and occurred after
complete resolution of the inception TIA. Those who received im-
aging only after a recurrent stroke and not in the interval between
inception TIA and recurrent stroke were excluded.
ABCD2 scores were calculated by local investigators after
face-to-face evaluation. Follow-up was by face-to-face or tele-
phone review or examination of clinical records. Brain infarction
was determined by either a dedicated study neurologist or radiol-
ogist or from routine reports in individual centers. In centers
where patients were imaged with both MRI and CT only MRI
results were recorded to avoid double counting of individuals.
For patients imaged with DWI, any acute infarction was re-
corded, irrespective of whether it was appropriate to the present-
ing symptoms. For patients imaged with CT, any infarction was
recorded, regardless of age, given the unreliability of distinguish-
ing between acute and old infarction. Changes attributed to leu-
koaraiosis were not recorded.
To study outcomes and predictors according to tissue-
defined criteria, subjects with time-defined TIA were subcatego-
rized as tissue positive or tissue-negative according to the
presence or absence of brain infarction as defined above. Tissue-
positive TIA therefore corresponded to stroke with rapid and
complete symptomatic recovery according to the ASA definition
and tissue-negative TIA corresponded to TIA.
Statistical analysis. To examine the predictive power of the
ABCD2 score, discrimination was studied using the area under
the receiver operator characteristic curve (AUC) with 95% con-
fidence interval (CI) using standard methods. Ideal discrimina-
tion produces an AUC of 1.0, and discrimination that is no
better than chance produces an AUC of 0.5. Analyses were done
with SPSS version 15.0 (SPSS, Inc., Chicago, IL).
Standard protocol approvals, registrations, and patient
consent. All collaborating centers received approval from local
ethical standards committees for the study, and written in-
formed consent for participation in the study was obtained
from all subjects.
RESULTS Table e-1 on the Neurology® Web site at
www.neurology.org describes the methods used in
each of the 12 centers. Two studies were population-
based,17,18 5 were from emergency departments
(EDs),19–23 and 5 were from specialist neurovascular
units.24 –28 Five studies used DWI only,21,22,26 –28 3
studies used CT imaging only,17,19,20 and 4 used a
combination of the 2 modalities.18,23–25 These last 4
Table 1 Total numbers of participants, numbers with infarction on brain





7 d, n (%) 90 d, n (%)
California20 CT 322 80 19 (5.9) 35 (10.9)
OXVASC17 CT 227 79 28 (12.3) 45 (19.8)
Cucchiara et al.24 DWI 96 22 4 (2.4) 5 (3.0)
CT 71 30
Lavallee et al.25 DWI 880 134 5 (0.5) 17 (1.6)
CT 204 33
SINPAC19 CT 274 53 10 (3.6) 15 (5.4)a
Calgary21 DWI 111 41 4 (3.6) 6 (5.4)
Calvet et al.26 DWI 339 136 5 (1.5) 10 (2.9)
Ay et al.28 DWI 586 200 28 (4.8) NA
Purroy et al.22 DWI 204 95 3 (1.5) 9 (4.4)
Stanford28 DWI 99 15 1 (1.0) 1b
NDSS18 DWI 125 30 2 (0.9) 10 (4.7)
CT 88 37
Asimos et al.23 DWI 766 211 36 (3.8) 38 (4.0)
CT 182 15
Abbreviations: DWI  diffusion-weighted MRI; NA  not available; NDSS  North Dublin
Stroke Study; OXVASC  Oxford Vascular Study; SINPAC  Societá Inter-regionale
Piemonte-Aosta Cerebrovasculopatie.
a Follow-up available only to 30 days.
b Follow-up to 90 days available for 85 subjects.
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studies contributed 2 cohorts each, 1 DWI and 1
CT. In 1 study,19 the ABCD score only was re-
corded, and this was substituted for the ABCD2
score in relevant analyses. In 3 cohorts, follow-up
data were either incomplete or unavailable beyond 7
days.19,27,28
Table 1 shows the rate of brain infarction ob-
served and the risk of recurrent stroke at 7 and 90
days. A total of 4,574 patients were included in the
study. Among 3,206 imaged with DWI, 884
(27.6%) had acute brain infarction and among 1,368
imaged with CT, 327 (23.9%) had acute or old in-
farction. Rates of infarction varied considerably be-
tween studies (15.2%28–46.6%22 in DWI cohorts,
and 8.2%23–42.0%18 in CT cohorts). Of those im-
aged with DWI and CT, 72 (2.2%; 95% CI 1.8–
2.8) and 73 (5.3%; 95% CI 4.2–6.7), respectively,
had a recurrent stroke at 7 days. Rates of recurrent
stroke differed between cohorts, with higher rates ob-
served in population-based and ED-based studies
and lower rates observed in studies based in neuro-
vascular units.
Table 2 shows the rate of recurrent stroke at 7 and
90 days categorized by ABCD2 scores and by the
presence or absence of infarction for DWI alone co-
horts and for CT and DWI cohorts combined. For
those imaged with DWI, pooled rates of recurrent
stroke at 7 days were 7.1% (95% CI 5.5–9.1) in
those with tissue-positive events, compared with
0.4% (0.2–0.7) in those with tissue-negative events
(p diff  0.0001). For those imaged with CT, corre-
sponding rates were 12.8% (9.3–17.4) and 3.0%
(2.0–4.2), respectively (p diff  0.0001).
Patients with infarction had higher ABCD2
scores than those without (p  0.0001, Mann-
Whitney U test), as shown in the figure. However,
the ABCD2 score was predictive of recurrent stroke
at 7 days in those with and without infarction. AUCs
for the prediction of stroke at 7 days by the ABCD2
score for tissue-positive and tissue-negative events
were 0.68 (95% CI 0.63– 0.73) and 0.73 (0.67–
0.80), respectively (p sig  0.0001 for both results, p
diff  0.17). For those imaged with DWI, corre-
sponding AUCs were 0.67 (0.61– 0.73) and 0.66
(0.54–0.78) (p sig  0.0001 for both results) and
for those imaged with CT, AUCs were 0.69 (0.62–
0.76) and 0.72 (0.65–0.80) (p sig  0.0001 for both
results). AUCs for prediction of recurrent stroke at
90 days were 0.66 (0.61– 0.71) and 0.69 (0.62–
0.76), respectively, for tissue-positive and tissue-
negative events overall (p sig  0.0001 for both
results), 0.69 (0.63– 0.75, p  0.0001) and 0.61
(0.50–0.72, p  0.1) for those imaged by DWI, and
Table 2 Number of strokes, number of patients, and stroke risk at 7 and 90 days by ABCD2 score in patients with and without infarction
for CT and DWI cohorts combined and DWI cohorts only
ABCD2 score
7 d 90 d
With infarction Without infarction With infarction Without infarction
Stroke No.
% Risk
(95% CI) Stroke No.
% Risk
(95% CI) Stroke No.
% Risk
(95% CI) Stroke No.
% Risk
(95% CI)
All CT and MRI
cohorts combined
<1 0 27 0.0 (0.0–0.0) 0 272 0.0 (0.0–0.0) 0 22 0.0 (0.0–0.0) 2 243 0.8 (0.1–3.0)
2 2 95 2.1 (0.3–7.6) 0 447 0.0 (0.0–0.0) 3 73 4.1 (0.8–12) 1 379 0.3 (0.0–1.5)
3 5 177 2.8 (0.9–6.6) 3 647 0.5 (0.1–1.4) 6 135 4.4 (1.6–9.7) 9 518 1.7 (0.8–3.3)
4 15 310 4.8 (2.7–8) 10 855 1.2 (0.6–2.2) 20 248 8.1 (4.9–12.5) 11 697 1.6 (0.8–2.8)
5 42 329 12.8 (9.2–17.3) 12 682 1.8 (0.9–3.1) 45 265 17.0 (12.2.7) 17 528 3.2 (1.9–5.2)
>6 41 273 15.0 (10.8–20.4) 15 460 3.3 (1.8–5.4) 41 215 19.1 (13.5.9) 21 377 5.6 (3.4–8.5)
Total 105 1,211 8.7 (7.1–10.5) 40 3,363 1.2 (0.8–1.6) 115 958 12 (9.9–14.4) 61 2,742 2.2 (1.7–2.9)
MRI cohorts only
<1 0 20 0.0 (0.0–0.0) 0 225 0.0 (0.0–0.0) 0 15 0.0 (0.0–0.0) 1 204 0.5 (0.0–2.7)
2 1 68 1.5 (0.0–8.2) 0 329 0.0 (0.0–0.0) 0 51 0.0 (0.0–0.0) 0 283 0.0 (0.0–0.0)
3 3 135 2.2 (0.5–6.5) 1 469 0.2 (0.0–1.2) 1 98 1.0 (0.0–5.7) 5 376 1.3 (0.4–3.1)
4 12 228 5.3 (2.7–9.2) 4 577 0.7 (0.2–1.8) 12 184 6.5 (3.4–11.4) 4 485 0.8 (0.2–2.1)
5 23 241 9.5 (6.0–14.3) 3 454 0.7 (0.1–1.9) 20 192 10.4 (6.4–16.1) 7 359 1.9 (0.8–4.0)
>6 24 192 12.5 (8.0–18.6) 1 268 0.4 (0.0–2.1) 20 144 13.9 (8.5–21.5) 2 215 0.9 (0.1–3.4)
Total 63 884 7.1 (5.5–9.1) 9 2,322 0.4 (0.2–0.7) 53 684 7.7 (5.8–10.1) 19 1,922 1.0 (0.6–1.5)
Abbreviations: CI  confidence interval; DWI  diffusion-weighted MRI.
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0.64 (0.56–0.71, p  0.001) and 0.69 (0.61–0.77,
p  0.0001) for those imaged with CT.
Comparable or even overlapping rates of recur-
rent stroke were observed in tissue-positive and
tissue-negative events, depending on ABCD2 score;
for instance, among DWI patients, the 90-day stroke
rate was 0.6% in tissue-positive events with ABCD2
3 compared with 1.2% in tissue-negative events
with ABCD2 3. Table 3 shows pooled stroke out-
comes at 7 days, categorized by infarction status and
ABCD2 score cutpoints of 0–3, 4–5, and 6–7, for
DWI and CT cohorts and all cohorts combined.
These cutpoints are often used to identify patients at
low, moderate, and high risk of early stroke.5,6
DISCUSSION The usefulness of a definition of a
condition in clinical medicine depends on whether it
informs clinicians and patients by reliably identifying
groups with a specific prognosis or requirement for
treatment. In this study, tissue-positive TIA corre-
sponded to stroke with rapid and complete recovery
according to the ASA definition. Our findings sup-
port the concept of this tissue-based definition of
TIA and stroke and show that DWI is superior to
CT on prognostic grounds.
The substantial difference in outcome between
these groups is clinically relevant and should influ-
ence management decisions involving the urgency of
treatment such as triage and admission to the hospi-
tal. For DWI cohorts, a 7-day stroke risk of 7.1% in
tissue-positive events probably necessitates hospital
admission or at least some other form of emergency
investigation and treatment, whereas a stroke rate of
0.4% at 7 days could represent a low enough risk for
patients to be managed safely on an outpatient basis.
This difference in outcome could also be exploited in
the efficient design of clinical trials of secondary pre-
vention by identifying subjects with a potential for
higher rates of outcome events, thereby reducing the
total numbers needed to recruit. Recent guidelines
highlight the importance of management in specialist
neurovascular units offering urgent treatment and in-
vestigations.4 – 6 Interestingly, when cohorts from
these units only are considered,24 –28 the observed
rate of stroke at 7 days was 1.9%, consistent with
the benefits of urgent treatment observed in the
EXPRESS and SOS-TIA studies.25,29
Of the 3,206 patients who underwent DWI, 884
(27.6%) were tissue-positive and 2,322 (72.4%)
were tissue-negative. Rates of recurrent stroke at 7
days in these groups were 7.1% vs 0.4%, respectively,
an 18-fold difference. In acute coronary syndromes
(ACSs), troponin levels are considered to generate
prognostic information by distinguishing between
tissue-positive and tissue-negative events. However,
in patients with non-ST elevation ACS, rates of re-
current myocardial infarction or death are 2- to
5-fold different in those with elevated vs normal lev-
els of troponin.30,31 Moreover, studies of ACS have
tended to use longer periods of follow-up and vary-
ing definitions of reinfarction, which may exaggerate
differences in observed rates. This comparison with
ACS underlines the predictive power and clinical
usefulness of infarction on DWI.
Figure Pooled analysis of association between ABCD2 score and presence of
infarction on diffusion-weighted imaging (DWI) or CT brain imaging
Odds ratios are relative to an ABCD2 score of 1.
Table 3 Numbers of strokes and numbers of patients at 7 days by ABCD2
score cutpoints of 0–3, 4–5, and 6–7 in patients with and
without infarction for cohorts pooled according to imaging
modality and overall
ABCD2 score cutpoint
No. of patients (% stroke risk, 95% CI)
With infarction Without infarction
DWI
0–3 4/223 (1.8, 0.5–4.6) 1/1, 023 (0.1, 0.0–0.5)
4–5 35/469 (7.5, 5.2–10.4) 7/1, 031 (0.7, 0.3–1.4)
6–7 24/192 (12.5, 8.0–18.6) 1/268 (0.4, 0.0–2.1)
CT
0–3 3/76 (3.9, 0.8–11.5) 3/343 (0.9, 0.2–2.6)
4–5 22/170 (12.9, 8.1–19.6) 15/506 (3.0, 1.7–4.9)
6–7 17/81 (21.0, 12.2–33.6) 14/192 (7.3, 4–12.2)
All
0–3 7/299 (2.3, 0.9–4.8) 3/1, 366 (0.2, 0.0–0.6)
4–5 57/639 (8.9, 6.8–11.6) 22/1, 537 (1.4, 0.9–2.2)
6–7 41/273 (15.0, 10.8–20.4) 15/460 (3.3, 1.8–5.4)
Abbreviations: CI  confidence interval; DWI  diffusion-weighted MRI.
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Although DWI was developed more than 20 years
ago,32 its technology continues to advance. Improve-
ments in magnetic field strength and spatial resolu-
tion with reductions in scan slice thickness are likely
to improve sensitivity for infarction.33 Compared
with follow-up brain imaging, the false-negative rate
for DWI is appreciable, with poorer detection of la-
cunar infarcts in the brainstem and internal capsule
areas.34 If the small group of patients without infarc-
tion on DWI who had early strokes represents those
with false-negative imaging, then prognostication is
likely to improve as DWI becomes more sensitive.
Moreover, our study used a blunt definition of the
presence of any acute infarct, whether correlating or
inappropriate to the presenting symptoms, which
may have diminished prognostic power. Similarly,
we did not distinguish some other factors that may
have yielded further prognostic information such as
vascular territory, region (cortical vs subcortical), age,
or multiplicity of infarcts.35
Studies of the prognostic yield of plain CT scan-
ning after TIA have yielded conflicting results. How-
ever, studies have tended to recruit subjects in the
subacute phase, reported longer-term vascular out-
comes and survival, and analyzed other imaging ab-
normalities such as leukoaraiosis in addition to
infarction.36 To our knowledge, there have only been
2 published studies in the acute phase of TIA specif-
ically addressing the predictive power of infarction
on CT imaging for early stroke recurrence.19,20 Both
reported a significantly higher rate of recurrent stroke
in tissue-positive cases. Although we used a prag-
matic definition of acute or old infarction in the cur-
rent study because of the uncertainty in reliably
determining infarct age on CT, those with tissue-
positive and tissue-negative events were still found to
have different outcomes (recurrent stroke rate at 7
days of 12.8% vs 3.0%). CT is less sensitive for acute
ischemia than DWI, but infarction on CT could be a
marker of particular stroke etiologies such as large
artery disease or cardioembolic stroke, possibly ex-
plaining predictive value in the acute phase. Alterna-
tively, (silent) infarction on CT is a marker for
vascular disease elsewhere or other vascular risk fac-
tors,36 but this association is more likely to explain
outcomes in the longer term. We did not find a sig-
nificant difference in predictive power of CT as mea-
sured by AUC in the 0 –7 vs 8 –90 day periods,
although our sample was not powered to detect such
a difference.
In addition to reduced sensitivity for ischemia,
CT also has the drawback of radiation exposure and
therefore is not recommended for TIA when MRI is
available and not contraindicated. However, our re-
sults show that, when MRI is unavailable, contrain-
dicated, or not tolerated, CT can yield useful
prognostic information. Further prognostication
may be possible using newer CT techniques such as
CT angiography and perfusion, but their role is cur-
rently uncertain.
Although the presence of infarction is the major
determinant of early stroke, we have found that the
ABCD2 score has predictive value in the acute phase
in both tissue-positive and tissue-negative patients,
identifying individuals at higher and lower risk
within both these groups. Some authors have
claimed that the predictive power of the ABCD2
score is explained mainly by its diagnostic function,
by discriminating between those with genuine TIA at
high risk of further vascular events and other non-
neurovascular diagnoses. The score has been found
to distinguish between these groups. 37,38 However,
the finding that the ABCD2 score is predictive in
TIA patients with infarction shows that the score
cannot work by diagnostic discrimination alone. We
argue that the score remains clinically useful, particu-
larly when applied to tissue-positive patients. In
those with DWI tissue-positive events, the observed
7-day stroke rate was 7.1% overall but was 1.8%,
7.5%, and 12.5% in those with ABCD2 scores of
0–3, 4–5, and 6–7, respectively (ABCD2 cutpoints
commonly used to identify low-, intermediate-, and
high-risk groups) (table 3). A similar degree of risk
stratification was observed in those with CT tissue-
positive events.
Table 3 also shows that recurrent stroke rates are
comparable in tissue-negative events with high
ABCD2 scores and tissue-positive events with low
ABCD2 scores. Indeed we found overlaps in stroke
rates in tissue-negative events with high clinical risk
scores and tissue-positive events with low clinical risk
scores at both 7 and 90 days in CT cohorts and at 90
days in DWI cohorts. These findings show that tran-
sient neurologic events represent a continuous spec-
trum of risk and support the use of a combined
approach to prognostication, using both clinical and
imaging information.7,8 The association between in-
farction and risk in the longer term has not been
addressed in large studies.
Although we believe our findings are valid, we
acknowledge some shortcomings. There was a con-
siderable difference in outcomes observed between
cohorts using DWI compared with those using CT.
Outcomes in observational studies of TIA depend on
the health care setting because of treatment effect
and referral bias.1 CT tended to be used in ED- and
population-based cohorts, and DWI was used in co-
horts from specialist units, so it is likely that the dif-
ference in observed stroke rates between CT and
DWI cohorts is partly explained by study methodol-
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ogy. If our results are to be generalized, they should
be calibrated according to the health care setting.
Scans were interpreted by individual centers, and
there was no central adjudication, potentially leading
to less reliability in interpretation but reflecting clin-
ical reality. Our findings are based on patients with
time-defined TIA, who, by definition, had transient
symptoms that resolved within 24 hours. Although
we have subcategorized these as tissue-positive and
tissue-negative, our findings cannot be generalized to
all tissue-defined stroke. Among those with a neuro-
logic deficit lasting longer than 24 hours, the risk of
subsequent stroke varies, with particularly high risk,
comparable to that of time-defined TIA, observed in
those with nondisabling symptoms and lower risk in
those with major or disabling deficits.39,40 It has been
proposed that a new syndrome—transient symptoms
with infarction—should be recognized because of the
differing prognosis between those with transient
symptoms with and without infarction and those
with a permanent deficit.15
In conclusion, we have found that subcategoriza-
tion of patients with TIA as defined by time-based
criteria into tissue-positive and tissue-negative
groups yields helpful prognostic information, espe-
cially when brain infarction is found on DWI. The
ABCD2 score further refines risk in both tissue-
positive and tissue-negative groups.
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